Cdkn2a-2A-DreERT2(p16-2A-DreERT2)
Nomenclature
C57BL/6JSmo-Cdkn2aem(2A-DreERT2)1Smoc
Cat. NO.
NM-KI-225086
Strain State
Repository Live
Gene Summary
Gene Symbol
Cdkn2a
Model Description
Validation Data
Fig.1 Detection of Cdkn2a expression in kidney, lung, liver and skin by qPCR. Cdkn2a mRNA was detected at comparable levels and exhibited similar expression profiles in both wild-type and heterozygous Cdkn2a-2A-DreERT2 knockin mice, indicating that the knockin allele did not disrupt the endogenous expression pattern of the gene. Kidney, lung, liver and skin RNA was extracted from 9-week-old male wild-type C57BL/6 (WT)(n=3) and heterozygous Cdkn2a-2A-DreERT2 knockin mice (HO)(n=3), then cDNA libraries were synthesized by reverse transcription, followed by qPCR with mouse Cdkn2a(F3/R3) and mouse Gapdh primers. Relative expression represents the mouse Cdkn2a(F3/R3) mRNA level relative to heterozygous Cdkn2a-2A-DreERT2 knockin mice expression in skin .
Abbr. M, marker; HE, heterozygous; WT, wild type.
Fig.2 Detection of DreERT2 expression in kidney, lung, liver and skin by qPCR. DreERT2 mRNA was detectable in heterozygous Cdkn2a-2A-DreERT2 knockin mice but not in wild-type mice. Kidney, lung, liver and skin RNA was extracted from 9-week-old male wild-type C57BL/6 (WT)(n=3) and heterozygous Cdkn2a-2A-DreERT2 knockin mice (HO) (n=3), then cDNA libraries were synthesized by reverse transcription, followed by qPCR with DreERT2 and mouse Gapdh primers. Relative expression represents the DreERT2 mRNA level relative to heterozygous Cdkn2a-2A-DreERT2 knockin mice expression in skin.
Abbr. M, marker; HE, heterozygous; WT, wild type.
You may also like
Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreWorkshop：Progress and Advances in Preclinical immuno-Oncology Research
SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.
Learn moreCustomizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!
At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
Learn more
